a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Continuing its strategy to divest non-core parts of its business, Caliper Life Sciences today announced it has reached an agreement to sell its RapidTrace solid phase extraction and TurboVap evaporation product lines to Biotage for $16.5 million in cash.

Biotage also assumes liabilities of about $500,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.